Asset Details
Do you wish to reserve the book?
Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review
Do you wish to request the book?
Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review
2024
Overview
Colorectal cancer (CRC) screening has been proven to reduce both mortality and the incidence of this disease. Most CRC screening programs are based on fecal immunochemical tests (FITs), which have a low participation rate. Searching for blood protein biomarkers can lead to the development of a more accepted screening test. The aim of this systematic review was to compare the diagnostic potential of the most promising serum protein biomarkers. A systematic review based on PRISMA guidelines was conducted in the PubMed and Web of Science databases between January 2010 and December 2023. Studies assessing blood protein biomarkers for CRC screening were included. The sensitivity, specificity, and area under the ROC curve of each biomarker were collected. Among 4685 screened studies, 94 were considered for analysis. Most of them were case–control studies, leading to an overestimation of the performance of candidate biomarkers. The performance of no protein biomarker or combination of biomarkers appears to match that of the FIT. Studies with a suitable design and population, testing new assay techniques, or based on algorithms combining FIT with serum tests are needed.
The search for a blood screening test for colorectal cancer is a major challenge. Many protein biomarkers have been identified as potentially interesting. However, their performance must be interpreted according to the design of the study. This systematic review reports protein biomarkers with the best potential for screening for colorectal cancer or advanced adenomas.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
